Fig. 8.

TG-101,209 promoted pancreatic cancer patient response to chemotherapy and immunotherapy. (A) The heatmap depicting nine regulators expression of 16 PAAD patients (B) Volcano plot describing differential expression genes between high and low groups. Bar plots of KEGG and GO pathways of differential expression genes. (C) GSEA analysis of high-expression group and low-expression-group, the pathways were selected under P < 0.05. CMap results of predicted potential drugs of high expression of nine regulators. (D) Pancreatic tumor cells were subcutaneously transplanted into 4-6-week-old C57/BL mice. The mice were administered GEM, TG-101,209, or GEM combined TG-101,209. Box plot illustrating quantitative comparisons of tumor size across different treatment groups and control groups. (E) K-M survival curve of tumor-bearing mice during dosing. Death of mice as the endpoint of the survival record. The transplanted tumor cells were injected into the mouse pancreas in situ. (F) The tumors were stripped out from mice, and the frozen sections were stained with anti-Ki67. DAPI staining was included to visualize the nuclei. (G) Line graph telling proliferation ability in different treatment groups of KPC1 and KPC2 cell lines. (H) Heat map displaying the interaction of GEM and TG-101,209. (I) Mice were subcutaneously injected with pancreatic tumor cells. Tumor-bearing mice were injected with anti-PD1, TG-101,209, or a combination of anti-PD1 and TG-101,209. Tumor growth curve showing growth rate and volume size until mice sacrificed. (J) Survival curves of orthotopic pancreatic tumor-bearing mice in control, anti-PD1, TG-101,209, and combined therapy groups. The time at which the mice were sacrificed was the time at which the survival curve was finally recorded. K. Flow cytometry sorting CD8 + T cell types and the mathematical statistics were made in CD8 + T cells, effector CD8 + T cells, and exhausted CD8 + T cells of different immunotherapy groups